Whatever happened to the next big thing?
$8b Millennium deal serves up reality check on lofty genomics expectations
The genomics revolution was not a flop. It just needs more time. Millennium Pharmaceuticals Inc. , the Cambridge biotech firm that came to symbolize the genomics breakthroughs of the past 10 years, was never able to both develop and market a single drug using its genomic expertise. Yesterday, Japanese drug maker Takeda Pharmaceutical Co. said it would buy the company ... (Full article: 753 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
